FIGURE 5 from Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription

Comparison of DEGs identified in MYC+ DLBCL cell lines to blood samples from enitociclib-treated patienst with MYC+ NHL. A, Comparison of significant DEGs (Padj ≤ 0.05, fold change ≥2) after at 4 hours pretreatment with 250 nmol/L enitociclib. Heat map showing gene intensity per sample relative to the average level across all samples. Individual genes are shown on the Y axis while samples are shown along the X axis. Red and blue cells correspond to higher and lower RNA-seq levels, respectively after 4 hours of treatment. B, Transcription factors MYC, JUNB, ZFP36 mRNA have statistically significant fold change downregulation with enitociclib treatment in DLBCL cell lines SU-DHL-4 and SU-DHL-10 where other 4 hours treatments do not. PHF23 and TP53RK were the most significantly DEGs with enitociclib treatment at both concentrations. * denotes Padj ≤ 0.05 and fold change ≥2.